Literature DB >> 19372587

ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Valerie S Hawthorne1, Wen-Chien Huang, Christopher L Neal, Ling-Min Tseng, Mien-Chie Hung, Dihua Yu.   

Abstract

Overexpression of the ErbB2 receptor tyrosine kinase is prevalent in approximately 30% of human breast cancers and confers Taxol resistance. Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1). However, the mechanism of ErbB2-mediated p21(Cip1) up-regulation is unclear. Here, we show that ErbB2 up-regulates p21(Cip1) transcription through increased Src activity in ErbB2-overexpressing cells. Src activation further activated signal transducer and activator of transcription 3 (STAT3) that recognizes a SIE binding site on the p21(Cip1) promoter required for ErbB2-mediated p21(Cip1) transcriptional up-regulation. Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells. Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells. Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372587      PMCID: PMC2689096          DOI: 10.1158/1541-7786.MCR-08-0316

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line.

Authors:  Shankar Sellappan; Rebecca Grijalva; Xiaoyan Zhou; Wentao Yang; Menashe Bar Eli; Gordon B Mills; Dihua Yu
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

2.  Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.

Authors:  Pedro J Real; Angels Sierra; Ana De Juan; Jose C Segovia; Jose M Lopez-Vega; Jose L Fernandez-Luna
Journal:  Oncogene       Date:  2002-10-31       Impact factor: 9.867

3.  Opposite regulation of myc and p21waf1 transcription by STAT3 proteins.

Authors:  Benjamin Barré; Sylvie Avril; Olivier Coqueret
Journal:  J Biol Chem       Date:  2002-11-15       Impact factor: 5.157

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

Review 6.  Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis.

Authors:  Corinne M Silva
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.

Authors:  Lois M Witters; Samuel M Santala; Linda Engle; Vernon Chinchilli; Allan Lipton
Journal:  Am J Clin Oncol       Date:  2003-02       Impact factor: 2.339

9.  The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells.

Authors:  Edgar Mendoza-Gamboa; Doris R Siwak; Ana M Tari
Journal:  Oncol Rep       Date:  2004-10       Impact factor: 3.906

10.  Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.

Authors:  Daniel DeArmond; Michael G Brattain; John Milburn Jessup; Jeffrey Kreisberg; Shazli Malik; Shujie Zhao; James W Freeman
Journal:  Oncogene       Date:  2003-10-30       Impact factor: 9.867

View more
  28 in total

1.  Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.

Authors:  Joomin Lee; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Carcinogenesis       Date:  2010-08-19       Impact factor: 4.944

2.  Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.

Authors:  Wendy Béguelin; María Celeste Díaz Flaqué; Cecilia J Proietti; Florencia Cayrol; Martín A Rivas; Mercedes Tkach; Cinthia Rosemblit; Johanna M Tocci; Eduardo H Charreau; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

3.  Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.

Authors:  Shulin Xiang; Robert T Dauchy; Aaron E Hoffman; David Pointer; Tripp Frasch; David E Blask; Steven M Hill
Journal:  J Pineal Res       Date:  2019-06-09       Impact factor: 13.007

4.  Diallyl trisulfide inhibits activation of signal transducer and activator of transcription 3 in prostate cancer cells in culture and in vivo.

Authors:  Kumar Chandra-Kuntal; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-19

5.  Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.

Authors:  Shau-Hsuan Li; Valerie S Hawthorne; Christopher L Neal; Sartaj Sanghera; Jia Xu; Jun Yang; Hua Guo; Patricia S Steeg; Dihua Yu
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

6.  Involvement of extracellular signal-regulated kinase (ERK1/2)-p53-p21 axis in mediating neural stem/progenitor cell cycle arrest in co-morbid HIV-drug abuse exposure.

Authors:  Shaily Malik; Rinki Saha; Pankaj Seth
Journal:  J Neuroimmune Pharmacol       Date:  2014-01-28       Impact factor: 4.147

7.  Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma.

Authors:  James A Bonner; Hoa Q Trummell; Christopher D Willey; Brian A Plants; Kevin P Raisch
Journal:  Radiother Oncol       Date:  2009-07-16       Impact factor: 6.280

8.  Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.

Authors:  Xinyan Wu; Muhammad Saddiq Zahari; Santosh Renuse; Raja Sekhar Nirujogi; Min-Sik Kim; Srikanth S Manda; Vered Stearns; Edward Gabrielson; Saraswati Sukumar; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2015-09-01       Impact factor: 5.911

9.  SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.

Authors:  Siyuan Zhang; Wen-Chien Huang; Lin Zhang; Chenyu Zhang; Frank J Lowery; Zhaoxi Ding; Hua Guo; Hai Wang; Suyun Huang; Aysegul A Sahin; Kenneth D Aldape; Patricia S Steeg; Dihua Yu
Journal:  Cancer Res       Date:  2013-08-01       Impact factor: 12.701

10.  Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Authors:  Cecilia J Proietti; Franco Izzo; María Celeste Díaz Flaqué; Rosalía Cordo Russo; Leandro Venturutti; María Florencia Mercogliano; Mara De Martino; Viviana Pineda; Sergio Muñoz; Pablo Guzmán; Juan C Roa; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Endocrinol       Date:  2015-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.